IKS and POLYMED, both in Medical Specialties. Monthly data through 2026-10-09. Change the comparison →
Share price change since Dec '24, the first month all 2 have a price: IKS -11%, POLYMED -39%.
Rebased at 2024-12. Monthly closes from each company's history.
Months with a missing value are left as gaps.
The share price return over 3 years, split into net profit growth, share count change and the change in P/E.
POLYMED: share price rose 13% over 3 years: +67 pts from net profit growth, −48 pts from the P/E change, −6 pts from share count change.
Not shown for IKS: earnings were negative at one end of the window or there is not enough history.
Segments are percentage points of the price return: price = P/E × net profit ÷ share count. These are the same numbers each company's own page shows.
Each cell is the company's percentile rank among its own sector peers that month. Darker is higher-ranked. Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Percentiles use today's listed companies in the sector and need at least 5 peers with a value.
| Metric | IKS | POLYMED |
|---|---|---|
| Share Price | ₹1716.60 | ₹1587.10 |
| Market Cap | ₹29447 cr | ₹16082 cr |
| P/E | 47.8x | 47.9x |
| P/B | 16.5x | 5.3x |
| P/S | 17.9x | 9.4x |
| ROCE | 44.0% | 13.0% |
| ROE | 34.5% | 11.0% |
| Operating margin | 46.0% | 28.0% |
| Revenue (TTM), indexed to 100 | ₹1648 cr | ₹1710 cr |
| Net Profit (TTM) | ₹616 cr | ₹336 cr |
| Debt / Equity | 0.1x | 0.1x |
| Cash Conversion Cycle | 97d | 267d |
| Promoter holding | 63.7% | 62.4% |
| FII Holding | 8.0% | 5.6% |
| DII Holding | 7.5% | 16.1% |
| 12M momentum | 4.3% | -20.6% |
| Drawdown from Peak | -10.6% | -44.8% |
| Cash conversion (3Y) | 0.8x | 0.8x |
| Interest cover | 59.2x | 31.0x |
| Share Count Change (1Y) | 0.0% | 0.0% |
| Volatility (1Y) | 34.2% | 42.3% |
Latest month in the data: 2026-10. Highlight marks the higher value, or the lower value for P/E, P/B, P/S, debt, working-capital days, share count change and volatility. It marks a number, not a better investment.
Comparison is descriptive and historical. Highlights mark the higher or lower value on a metric, not a better investment. Not investment advice; ApnaFunda is not a SEBI-registered research analyst.